Sana highlights preclinical data from Hypoimmune, Fusogen platforms at ISSCR

Sana Biotechnology announced preclinical data from six presentations, including two oral presentations, at the International Society for Stem Cell Research, ISSCR, 2023 Annual Meeting. Oral Presentations: On Thursday, June 15, an oral presentation titled “Human Hypoimmune Primary Pancreatic Islets Evade Allogeneic and Autoimmune Rejection Without Immunosuppression and Alleviate Diabetes in Humanized Mice” featured data from in vitro and in vivo studies of human hypoimmune islet cells. The data demonstrated that HIP islet cells were similar in size, cell type composition, and in vitro insulin secretion as wild-type islet cells, showing that HIP engineering itself does not impact islet cell morphology or endocrine function. On Thursday, June 15, a second oral presentation titled “In Vivo Delivery of Genetic Payloads to Human Hematopoietic Stem/Progenitor Cells” featured data demonstrating the ability of Sana‘s fusogen platform to deliver genetic payloads to resting human hematopoietic stem/progenitor cells and access human HSPCs in both the peripheral blood and bone marrow of humanized mice. Poster Presentations: On Wednesday, June 14, poster #2082 titled “Hypoimmune Rhesus Macaque Induced Pluripotent Stem Cells Achieve Long-Term Survival in Fully Immunocompetent Allogeneic Recipients” detailed data on the ability of Sana’s HIP-modified allogeneic cells to escape immune detection in non-human primates in the absence of immune suppression. On Wednesday, June 14, poster #2034 titled “Engineered Hypoimmune CAR T Cells Survive, Function, and Persist in Immunocompetent Allogeneic Humanized Mice” outlined data evaluating HIP CD19-directed CAR T cells versus unmodified CD19-directed CAR T cells in three-month persistence studies with allogeneic humanized mice. On Thursday, June 15, poster #1122 titled “Standing Out From the Crowd: Stem Cell-Derived Islet Cells Function Independent of Clustering When Transplanted Intramuscularly” outlined data from mice that received stem cell-derived islet cells that were intramuscularly implanted using standard clusters, standard clusters disaggregated prior to implantation, or cells differentiated without aggregation into clusters. On Friday, June 16, poster #166 titled “Stem Cell Derived Islet Cells Show Robust Survival and Function When Transplanted in the Muscle Without Need for Additional Bioscaffolding” presented data on the effectiveness of stem cell-derived islet cells using intramuscular implant sites in immunodeficient diabetic mice. The studies showed that these fully differentiated SC-islets can be delivered intramuscularly with robust function and without the need for bioscaffolding.